Article
VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis.
Acta oncologica (Stockholm, Sweden) - 1 Jan 2014
Beuselinck Benoit, Karadimou Alexandra, Lambrechts Diether, Claes Bart, Wolter Pascal, Couchy Gabrielle, Berkers Joost, van Poppel Hendrik, Paridaens Robert, Schöffski Patrick, Méjean Arnaud, Verkarre Virginie, Lerut Evelyne, Joly Florence, Lebret Thierry, Gravis Gwénaelle, Deplanque Gael, Descazeaud Aurélien, Leclercq Nathalie Rioux, Molinié Vincent, Patard Jean-Jacques, Teghom Corine, Elaidi Reza, Zucman-Rossi Jessica, Oudard Stéphane
Abstract excerpt
BACKGROUND: There are no validated markers that predict outcome in metastatic renal cell cancer (mRCC) patients treated with sunitinib. Recently, single nucleotide polymorphism (SNP) rs9582036 in VEGFR1 has been proposed as a predictor of progression-free survival (PFS) and overall survival (OS) to bevacizumab in patients with pancreatic cancer and rs7993418 in VEGFR1 as predictor for PFS in mRCC-patients treated...
Read the complete abstract on PubMed